Sonoma Pharmaceuticals, Inc. 8-K

What Happened
Sonoma Pharmaceuticals, Inc. (SNOA) filed an 8‑K on June 18, 2026 reporting a supplement to its September 26, 2025 prospectus supplement under an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. The company increased the aggregate offering price available under the ATM program to $3,641,703. Since entering the Agreement, Sonoma has sold 173,073 shares for total proceeds of $574,633.

Key Details

• ATM agent: Ladenburg Thalmann & Co. Inc.; Agreement dated September 26, 2025.
• Registration: Form S-3 (File No. 333-275311) declared effective November 20, 2023; prospectus supplement filed September 26, 2025.
• Sales to date (Sept 26, 2025 through filing): 173,073 shares sold for $574,633.
• New aggregate offering capacity after June 18, 2026 supplement: $3,641,703 (includes $1,495,830 of previously registered but unsold common stock).
• Legal: Opinion of Polsinelli PC on validity of shares filed as Exhibit 5.1.

Why It Matters
The amendment increases Sonoma’s flexibility to raise up to $3.64 million through its at‑the‑market (ATM) program. For investors, that means the company has an active mechanism to obtain capital quickly, which can support operations or growth but also could dilute existing shareholders if shares are sold. The filing is procedural and includes counsel’s opinion; it does not itself sell shares or solicit offers in jurisdictions where such sales would be unlawful.